JPMorgan has increased its price target for Eli Lilly to $1,150 from $1,050, reiterating an Overweight rating on the stock. The investment bank's optimism is fueled by the strong outlook for the company's obesity and diabetes medications, highlighting ongoing U.S. market share gains for its incretin portfolio. The bank anticipates significant growth for Lilly in 2026 and beyond, pointing to the large and undertreated international market for obesity treatments. This positive analyst revision follows other recent developments for the pharmaceutical giant. Eli Lilly recently gained marketing approval in India for donanemab, its treatment for early-stage Alzheimer's disease. The approval from India's Central Drugs Standard Control Organization allows for the distribution of the drug in a significant new market, targeting the growing number of patients with the neurodegenerative condition.